A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Completed · Phase 2 · Has a placebo group

Conditions studied: Autoimmune Hepatitis

In brief

This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

Key facts

Study ID
NCT05569759
Run by
Kezar Life Sciences, Inc.
People needed
24
Starts
2023-05-23
Expected to finish
2025-04-30
Last updated by the study team
2026-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.